Impacts of tirofiban on plasma levels of sCD40L, HIF-1α, and iNOS
10.3969/j.issn.1006-5725.2014.15.046
- VernacularTitle:替罗非班对急诊PCI术后患者血清可溶性CD40配体、缺氧诱导因子α、诱导性一氧化氮合成酶的影响
- Author:
Huijuan LI
;
Huipu XU
- Publication Type:Journal Article
- Keywords:
Myocardial infarction;
Intervention;
Tirofiban;
sCD40L;
HIF-1α;
iNOS
- From:
The Journal of Practical Medicine
2014;(15):2481-2483
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the impacts of tirofiban on plasma levels of sCD40L and HIF-1α, and iNOS activity in patients undergoing emergency PCI. Methods A total of 80 patients with acute STEMI received primary PCI were randomly divided into a tirofiban group and a control group. The tirofiban group received tirofiban of 10 μg/kg, followed by an infusion of tirofiban of 0.15 μg/(kg·min) for 24 ~ 36 hours; while the control group directly received stent implantation after balloon angioplasty. Plasma levels of sCD40L , HIF-1α, and iNOS were detected in baselines and 12 hours after the procedrue. Results 12 hours after the procedure, serum levels of sCD40L, HIF-1α, and iNOS were higher than the baseline levels (P < 0.05). As compared with the control group, levels of sCD40L, HIF-1α, and iNOS were significantly lower (P < 0.05). Conclusions This study preliminarily sugguests tirofiban has a role in anti-inflammation and protection of vascular endothelium besides anti-platelet effects.
